MUSSOLIN, LARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.527
EU - Europa 692
AS - Asia 645
SA - Sud America 2
AF - Africa 1
Totale 5.867
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.499
SG - Singapore 300
CN - Cina 291
IT - Italia 279
FI - Finlandia 110
SE - Svezia 87
FR - Francia 58
DE - Germania 48
GB - Regno Unito 45
CA - Canada 28
VN - Vietnam 25
UA - Ucraina 24
IN - India 20
RU - Federazione Russa 13
HK - Hong Kong 9
IE - Irlanda 8
NL - Olanda 6
BE - Belgio 2
ES - Italia 2
GR - Grecia 2
RO - Romania 2
BG - Bulgaria 1
BR - Brasile 1
CH - Svizzera 1
DK - Danimarca 1
EC - Ecuador 1
ER - Eritrea 1
LU - Lussemburgo 1
MD - Moldavia 1
PL - Polonia 1
Totale 5.867
Salva come PNG Salva come JPEG
Città #
Fairfield 716
Woodbridge 397
Ann Arbor 381
Chandler 356
Ashburn 304
Houston 294
Cambridge 283
Seattle 248
Singapore 234
Wilmington 226
Boardman 132
Santa Clara 129
Padova 128
San Diego 100
Jacksonville 90
Princeton 89
Medford 78
Beijing 73
Des Moines 59
Helsinki 57
Nanjing 34
Guangzhou 27
Dong Ket 25
North York 25
Roxbury 25
Milan 23
London 15
New York 13
Shenyang 13
Nanchang 12
Hebei 11
Norwalk 11
Jinan 9
Dublin 8
Fiesso d'Artico 8
Jiaxing 8
Dallas 7
Ogden 7
Pune 7
Hangzhou 6
Cinisello Balsamo 5
Hong Kong 5
Shanghai 5
Tianjin 5
Islington 4
Phoenix 4
Changsha 3
Chicago 3
Florence 3
Kharkiv 3
Kilburn 3
Lappeenranta 3
Munich 3
Redwood City 3
Rome 3
Zhengzhou 3
Albignasego 2
Amsterdam 2
Arezzo 2
Athens 2
Bagnaria Arsa 2
Bari 2
Borås 2
Brussels 2
Central 2
Chiampo 2
Coimbatore 2
Eboli 2
Forlì 2
Frankfurt am Main 2
Fuzhou 2
Hounslow 2
Hyderabad 2
Indiana 2
Kunming 2
Lanzhou 2
Leawood 2
Limena 2
Lissone 2
Los Angeles 2
L’Aquila 2
Messina 2
Modena 2
Ottawa 2
Pescara 2
Southwark 2
Taiyuan 2
Turin 2
Valencia 2
Venice 2
Verona 2
Vicenza 2
Abano Terme 1
Acton 1
Alpharetta 1
Arce 1
Asmara 1
Belluno 1
Bergamo 1
Biella 1
Totale 4.806
Salva come PNG Salva come JPEG
Nome #
ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors. 174
A high definition picture of key genes and pathways mutated in pediatric follicular lymphoma 145
Mediastinal Burkitt lymphoma in childhood. 133
Abrupt relapse of ALK-positive lymphoma after discontinuation of crizotinib 116
Minimal Disseminated Disease in High-Risk Burkitt's Lymphoma Identifies Patients With Different Prognosis 115
Pre-clinical evaluation of second generation pim inhibitors for the treatment of t-cell acute lymphoblastic leukemia and lymphoma 111
MODULATION OF MICRORNA EXPRESSION IN HUMAN T CELL DEVELOPMENT: TARGETING OF NOTCH3 BY MIR-150 109
Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: The AIEOP experience 105
Prognostic factors in paediatric anaplastic large cell lymphoma: role of ALK 98
Detection of prognostic factors in children and adolescents with Burkitt and Diffuse Large B-Cell Lymphoma treated with the AIEOP LNH-97 protocol 98
Clinical impact of miR-223 expression in pediatric T-Cell lymphoblastic lymphoma 94
Plasma small-extracellular vesicles enriched in miR-122-5p promote disease aggressiveness in pediatric anaplastic large-cell lymphoma 93
An aberrant microRNA signature in childhood T-cell lymphoblastic lymphoma affecting CDKN1B expression, NOTCH1 and growth factor signaling pathways. 93
Long-term results of the AIEOP LNH-97 protocol for childhood lymphoblastic lymphoma 93
Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150 90
Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis. 89
miR-939 acts as tumor suppressor by modulating JUNB transcriptional activity in pediatric anaplastic large cell lymphoma 88
Low miR-214-5p Expression Correlates With Aggressive Subtypes of Pediatric ALCL With Non-Common Histology 87
Small RNAs in Circulating Exosomes of Cancer Patients: A Minireview 84
RNY4 in Circulating Exosomes of Patients With Pediatric Anaplastic Large Cell Lymphoma: An Active Player? 83
A unique case of pediatric large B-cell lymphoma with the clathrin-ALK gene rearrangement 82
Consequences of heat shock protein 72 (Hsp72) expression and activity on stress-induced apoptosis in CD30(+) NPM-ALK(+) anaplastic large-cell lymphomas. 82
Kinetics of Circulating Plasma Cell-Free DNA in Paediatric Classical Hodgkin Lymphoma 81
Pediatric IgG4-related lymphadenopathy: A rare condition associated with autoimmunity and lymphoproliferative disorders 80
Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. 80
MicroRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas. 79
Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report 79
Paediatric non-Hodgkin lymphoma - perspectives in translational biology 79
Proteomic profiles and biological processes of relapsed vs. Non-relapsed pediatric hodgkin lymphoma 79
Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood 78
The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity 78
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. 77
Course of anti-ALK antibody titres during chemotherapy in children with anaplastic large cell lymphoma 77
MiR&moRe2: A bioinformatics tool to characterize microRNAs and microRNA-offset RNAs from small RNA-Seq data 77
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 75
MiR-26a-5p as a Reference to Normalize MicroRNA qRT-PCR Levels in Plasma Exosomes of Pediatric Hematological Malignancies 74
Increased Tenascin C, Osteopontin and HSP90 Levels in Plasmatic Small Extracellular Vesicles of Pediatric ALK-Positive Anaplastic Large Cell Lymphoma: New Prognostic Biomarkers? 74
Comparative analysis of MRD by LD-PCR and Ig gene rearrangements in mature B-ALL of childhood 73
Histiocytic sarcoma arising in a child affected by Burkitt lymphoma, with t(8;14)(q24;q32) positivity in both tumors 73
Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead 71
Minimal residual disease analysis in childhood mature B-cell leukaemia/lymphoma treated with AIEOP LNH-97 protocol with/without anti-CD20 administration 71
Non-Hodgkin lymphoma in children with an associated inherited condition: A retrospective analysis of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) 70
Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis 70
The revised International Paediatric Non-Hodgkin Lymphoma Staging System (IPNHLSS): a test of applicability 70
Genomic and Transcriptomic Analyses Revealed Differences and Similarities Between T-Lbl and T-ALL. 67
Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial 65
Histology of pediatric classic Hodgkin lymphoma: From diagnosis to prognostic stratification 63
Epstein-Barr virus BART microRNAs in EBV- associated Hodgkin lymphoma and gastric cancer 63
Analisi molecolare combinata di MYC-IGH e del riarrangiamento delle IG per la valutazione di malattia minima residua nella leucemia a cellule B mature 61
Impatto clinico della soppressione di SIK1 da parte di miR-223 in pazienti pediatrici affetti da linfoma linfoblastico T 61
Proteomic identification of plasma biomarkers in children and adolescents with recurrent hodgkin lymphoma 60
IgGene rearrangements as PCR Targest for MRD analysis in pediatric B-all and Burkitt's lymphoma and comparison with T(8;14) detection by LD-PCR 59
Minimal disseminated disease in high-risk Burkitt's lymphoma identifies patients with different prognosis. 59
Monoallelic mutations of the perforin gene may represent a predisposing factor to childhood anaplastic large cell lymphoma. 58
Identification of Snps and Indels mutation in ALK kinase domain by 454 massive parallel pyrosequencing 56
Ruxolitinib as a novel therapeutic option for poor prognosis t-lbl pediatric patients 55
T-cell lymphoblastic lymphoma shows differences and similarities with T-cell acute lymphoblastic leukemia by genomic and gene expression analyses. 52
TCR-Based RQ-PCR Assay for MDD and MRD Assessment in T-Cell Lymphoblastic Lymphoma of childhood 50
Prognostic Role of Minimal Disseminated Disease and NOTCH1/FBXW7 Mutational Status in Children with Lymphoblastic Lymphoma: The AIEOP Experience 50
HLA-G+3027 polymorphism is associated with tumor relapse in pediatric Hodgkin's lymphoma 49
Nuovi meccanismi molecolari e marcatori diagnostici nel linfoma follicolare pediatrico. 48
Regolazione dell'espressione e funzione di NPM-ALK nel Linfoma Anaplastico a Grandi Cellule: analisi mutazionale del complesso NPM-ALK/HSP90 ed implicazione sulla stabilità proteica 45
Growth inhibition and induction of apoptosi in ALCL lymphoma cells treated with the cdk inhibitor flavopiridol 44
Droplet digital PCR improves IG-/TR-based MRD risk definition in childhood B-cell precursor acute lymphoblastic leukemia 41
Droplet microfluidic platform for extracellular vesicle isolation based on magnetic bead handling 40
Risposta immunologica umorale anti-ALK ed attività  eparanasica nel linfoma anaplastico a grandi cellule pediatrico: due muovi marker biologici? 40
Stratificazione dei pazienti affetti da ALCL in base alla risposta umorale Anti-ALK e alla Malattia Minima Disseminata: studio collaborativo AIEOP-BFM 39
ANALISI MUTAZIONALE DELL’ONCOGENE NPM-ALK DERIVATO DALLA TRASLOCAZIONE RECIPROCA T(2;5)(P23;Q35)E IMPLICAZIONI FUNZIONALI SUL PRODOTTO PROTEICO 38
RISPOSTA UMORALE ANTI-ALK E MALATTIA MINIMA RESIDUA NEL LINFOMA ANAPLASTICO A GRANDI CELLULE (ALCL) PEDIATRICO 37
Long-distance PCR for t(8;14) in the characterization of Burkitt's Lymphomas and for the study of minimal residual disease 36
Phosphoproteomic Analysis Reveals a Different Proteomic Profile in Pediatric Patients With T-Cell Lymphoblastic Lymphoma or T-Cell Acute Lymphoblastic Leukemia 35
Primary mediastinal large B-cell lymphoma: Outcome of a series of pediatric patients treated with high-dose methotrexate and cytarabine plus anti-CD20. 35
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 35
Modificazioni del ciclo cellulare come nuova strategia terapeutica nei linfomi ALCL pediatrici 34
Outcome of acute B-cell lymphoblastic leukemia of childhood treated with ALEOP LNH-97 protocol 34
MRD Strategies in Burkitt Lymphoma 33
Caratterizzazione biologica dei Linfomi Linfoblastici pediatrici pediatrici della Linea T: differenze e similarità con la Leucemia Linfoblastica T 32
Linfoma anaplastico a grandi cellule (ALCL): esiste un ruolo per l'analisi citogenetica? 31
Bortezomib and Flavopiridol combination induces down regulation of Mcl-1, mitochondrial permeabilization and cell death in ALCL cells 30
Burkitt lymphoma of mediastinum: an unusual localization at diagnosis in childhood 30
[18F]FDG PET-MR in the Evaluation and Follow-Up of Incidental Bone Ischemic Lesions in a Mono-Center Cohort of Pediatric Patients Affected by Hodgkin’s Lymphoma 30
Mutazioni monoalleliche di PRF1 contribuiscono alla predisposizione allo sviluppo di linfoma anaplastico a grandi cellule in età pediatruca 28
T-LBL and T-ALL: differences and similarities detected by genomic and transcriptomic analyses 25
Proteomic exploration of plasma exosomes and other small extracellular vesicles in pediatric hodgkin lymphoma: A potential source of biomarkers for relapse occurrence 24
Successful Treatment of an EBV-positive Diffuse Large B-Cell Lymphoma in a Patient with Trisomy 21 23
Minimal Disease Monitoring in Pediatric Non-Hodgkin's Lymphoma: Current Clinical Application and Future Challenges 22
Large B-cell lymphoma with IRF4 rearrangement: a multi-centric study with focus on potential misleading phenotypes 19
Quantitative Plasma Proteomics to Identify Candidate Biomarkers of Relapse in Pediatric/Adolescent Hodgkin Lymphoma 17
MiR-146a-5p enrichment in small-extracellular vesicles of relapsed pediatric ALCL patients promotes macrophages infiltration and differentiation 16
TP53 DNA binding domain mutational status and rituximab-based treatment are independent prognostic factors for pediatric Burkitt lymphoma patients stratification 16
Primary breast lymphoma of childhood: a case report and review of literature 16
Biopathology of childhood, adolescent and young adult non-Hodgkin lymphoma 14
Quantitative assessment of minimal residual disease for monitoring of paediatric patients with relapsed/refractory anaplastic large‐cell lymphoma treated with brentuximab vedotin: A case series 14
Brentuximab vedotin in the treatment of paediatric patients with relapsed or refractory Hodgkin's lymphoma: Results of a real‐life study 13
BCAT1 is a NOTCH1 target and sustains the oncogenic function of NOTCH1 12
Higher accuracy of surgical over core needle biopsy for the diagnosis of lymphoproliferative disorders 12
Preliminary Study of the Relationship between Osteopontin and Relapsed Hodgkin's Lymphoma 12
Biopathology of childhood, adolescent and young adult non-Hodgkin lymphoma 11
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas 10
Promising drugs and treatment options for pediatric and adolescent patients with Hodgkin lymphoma 10
Totale 5.936
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.245
article - articoli 25.560
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.805
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020552 0 0 0 0 0 79 76 93 101 98 63 42
2020/2021929 27 52 13 193 39 32 40 93 108 122 99 111
2021/20221.043 54 115 92 99 37 83 59 113 45 33 97 216
2022/2023798 178 73 30 56 116 80 3 45 113 38 57 9
2023/2024484 35 76 54 43 17 40 54 8 14 9 61 73
2024/2025781 24 199 112 72 337 37 0 0 0 0 0 0
Totale 5.984